WESTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health (OPK) company, today announced the initiation and recent dosing of the first patient in a Phase 1/2a clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results